Last updated: August 23, 2026
Answer a few questions to find clinical trials matched to your specific weight-loss and obesity situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Find matching trials →Already approved: Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management; tirzepatide is also approved for obstructive sleep apnea in adults with obesity (SURMOUNT-OSA). Liraglutide (Saxenda), naltrexone/bupropion (Contrave), phentermine/topiramate (Qsymia), and orlistat remain approved options. The trials below test next-generation agents and combinations that are still investigational.
The biggest story in obesity medicine is the move from single-hormone GLP-1 drugs to agents that hit two or three gut/metabolic hormone receptors at once (GLP-1, GIP, glucagon), aiming for greater weight loss. Tirzepatide (GLP-1/GIP) is already approved; the next wave is in trials:
Already approved in this class: tirzepatide (Zepbound, GLP-1/GIP dual agonist) for chronic weight management and for obstructive sleep apnea. If you want to see which incretin trials fit your BMI and history, match your profile in minutes.
GLP-1 receptor agonists are the backbone of modern weight-loss pharmacology. Trials are testing oral and next-generation versions that could broaden access beyond weekly injections:
Already approved: semaglutide (Wegovy, weekly injection) and liraglutide (Saxenda, daily injection) for chronic weight management.
Amylin analogs work through a satiety pathway complementary to GLP-1, and combining the two is a leading strategy for deeper, more durable weight loss:
Rapid weight loss can reduce lean muscle as well as fat. A growing set of trials adds a muscle-sparing agent to an incretin backbone so that more of the loss is fat:
Many obesity trials enroll patients who also have a weight-related condition — obstructive sleep apnea, type 2 diabetes, cardiovascular disease, or a post-surgical setting. The wizard can account for these when matching:
For rare monogenic and hypothalamic obesity syndromes, treatments target the brain's melanocortin (MC4R) pathway rather than gut hormones:
Beyond drugs, obesity trials also test endoscopic and bariatric procedures — less invasive than traditional surgery, or head-to-head against it:
How do I find obesity clinical trials?
Answer a few questions in ClinTrialFinder to get AI-matched obesity and weight-loss trials in minutes. The tool considers your BMI, weight-related conditions (type 2 diabetes, obstructive sleep apnea, cardiovascular disease, MASH/fatty liver), prior weight-loss therapies (GLP-1 agonists, bariatric surgery), and goals to find the most relevant recruiting trials. It is free and needs no sign-up.
What obesity trials are currently recruiting?
There are 932 recruiting interventional obesity trials in August 2026, of which 66 are Phase 3. They span the incretin frontier — GLP-1 receptor agonists (semaglutide, oral semaglutide, ecnoglutide), GLP-1/GIP dual agonists (tirzepatide), triple GLP-1/GIP/glucagon agonists (retatrutide/LY3437943), GLP-1/glucagon dual agonists (survodutide, mazdutide), amylin combinations (CagriSema = cagrilintide + semaglutide), and oral small-molecule agonists (orforglipron) — plus muscle-preserving agents (bimagrumab), treatments for genetic/hypothalamic obesity (setmelanotide), and endoscopic and bariatric-surgery approaches.
What is retatrutide and is it in clinical trials for obesity?
Retatrutide (LY3437943) is an investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors — the next step beyond single (semaglutide) and dual (tirzepatide) incretin agonists, and one of the deepest weight-loss effects reported in trials to date. It is still investigational and not FDA-approved. Recruiting studies include NCT07467447 (Phase 2). Ask your physician whether you may qualify, or match your profile with ClinTrialFinder to see recruiting triple-agonist and other incretin trials.
Are GLP-1 weight-loss drugs like tirzepatide and semaglutide already approved, or only in trials?
Both. Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management, and tirzepatide is also approved for obstructive sleep apnea in adults with obesity (SURMOUNT-OSA). At the same time, hundreds of trials are recruiting to test next-generation agents (triple agonist retatrutide, amylin combination CagriSema, oral orforglipron and oral semaglutide, survodutide, mazdutide), new combinations, muscle-preserving strategies, and cardiovascular / metabolic outcomes. A clinical trial may offer access to an investigational therapy or additional monitoring — discuss the trade-offs with your physician.
Find Obesity Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find weight-loss trials based on your BMI, weight-related conditions, and prior therapies.
Find Matching Trials